ERBB2 amplification was most prevalent in GEC (15.5%), salivary gland (11.8%), bladder (10.9%), uterine (10.3%), and breast (9.9%) cancers, whereas ERBB3 amplification was most prevalent in small bowel (2.4%), uterine (2.2%), GEC (1.9%), biliary tract (1.5%), and ovarian (1.2%) cancers (Fig. 1A and B). This evidence concerns the gene ERBB2 and cancer.